دورية أكاديمية
Trough level of infliximab is useful for assessing mucosal healing in Crohn's disease: a prospective cohort study.
| العنوان: | Trough level of infliximab is useful for assessing mucosal healing in Crohn's disease: a prospective cohort study. |
|---|---|
| المؤلفون: | Koga A; Department of Gastroenterology, Fukuoka University Chikushi Hospital, Chikushino, Japan., Matsui T; Department of Gastroenterology, Fukuoka University Chikushi Hospital, Chikushino, Japan., Takatsu N; Department of Gastroenterology, Fukuoka University Chikushi Hospital, Chikushino, Japan., Takada Y; Department of Gastroenterology, Fukuoka University Chikushi Hospital, Chikushino, Japan., Kishi M; Department of Gastroenterology, Fukuoka University Chikushi Hospital, Chikushino, Japan., Yano Y; Department of Gastroenterology, Fukuoka University Chikushi Hospital, Chikushino, Japan., Beppu T; Department of Gastroenterology, Fukuoka University Chikushi Hospital, Chikushino, Japan., Ono Y; Department of Gastroenterology, Fukuoka University Chikushi Hospital, Chikushino, Japan., Ninomiya K; Department of Gastroenterology, Fukuoka University Chikushi Hospital, Chikushino, Japan., Hirai F; Department of Gastroenterology, Fukuoka University Chikushi Hospital, Chikushino, Japan., Nagahama T; Department of Gastroenterology, Fukuoka University Chikushi Hospital, Chikushino, Japan., Hisabe T; Department of Gastroenterology, Fukuoka University Chikushi Hospital, Chikushino, Japan., Takaki Y; Department of Gastroenterology, Fukuoka University Chikushi Hospital, Chikushino, Japan., Yao K; Department of Gastroenterology, Fukuoka University Chikushi Hospital, Chikushino, Japan., Imaeda H; Department of Medicine, Shiga University of Medical Science, Otsu, Japan., Andoh A; Department of Medicine, Shiga University of Medical Science, Otsu, Japan. |
| المصدر: | Intestinal research [Intest Res] 2018 Apr; Vol. 16 (2), pp. 223-232. Date of Electronic Publication: 2018 Apr 30. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Taehan Chang Yŏn'gu Hakhoe Country of Publication: Korea (South) NLM ID: 101572802 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1598-9100 (Print) Linking ISSN: 15989100 NLM ISO Abbreviation: Intest Res Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Sŏul : Taehan Chang Yŏn'gu Hakhoe |
| مستخلص: | Background/aims: Decreased trough levels of infliximab (TLI) and antibodies to infliximab (ATI) are associated with loss of response (LOR) in Crohn's disease. Two prospective studies were conducted to determine whether TLI or ATI better correlates with LOR (Study 1), and whether TLI could become a predictor of mucosal healing (MH) (Study 2). Methods: Study 1 was conducted in 108 patients, including those with LOR and remission to compare ATI and TLI in discriminating the 2 conditions based on receiver operating characteristic (ROC) curve analyses. Study 2 involved 35 patients who were evaluated endoscopically. Results: In Study 1, there were no differences between the 2 assays in ROC curve analyses; the TLI cutoff value for LOR was 2.6 µg/mL (sensitivity, 70.9%; specificity, 79.2%), and the ATI cutoff value was 4.9 µg/mL (sensitivity, 65.5%; specificity, 67.9%). The AUROC (area under the ROC curve) of TLI was greater than that of ATI. AUROC was useful for discriminating between the 2 conditions. In Study 2, the TLI was significantly higher in the colonic MH group than in the non-MH group (2.7 µg/mL vs. 0.5 µg/mL, P =0.032). Conclusions: TLI is better than ATI for clinically diagnosing LOR, and a correlation was observed between TLI and colonic MH. Competing Interests: CONFLICT OF INTEREST: No potential conflict of interest relevant to this article was reported. |
| References: | Clin Gastroenterol Hepatol. 2016 Apr;14 (4):550-557.e2. (PMID: 26538204) Dig Endosc. 2015 Jan;27(1):73-81. (PMID: 24833527) Lancet. 2002 May 4;359(9317):1541-9. (PMID: 12047962) Scand J Gastroenterol. 2011 Mar;46(3):310-8. (PMID: 21087119) Gut. 2014 Aug;63(8):1258-64. (PMID: 24041539) Inflamm Bowel Dis. 2009 Sep;15(9):1295-301. (PMID: 19340881) J Gastroenterol. 2014 Jan;49(1):100-9. (PMID: 23575576) Aliment Pharmacol Ther. 2011 Jul;34(1):1-10. (PMID: 21539588) Aliment Pharmacol Ther. 2011 May;33(9):987-95. (PMID: 21366636) Am J Gastroenterol. 2013 Jun;108(6):962-71. (PMID: 23419382) Arthritis Rheum. 1998 Sep;41(9):1552-63. (PMID: 9751087) Gastroenterology. 1976 Mar;70(3):439-44. (PMID: 1248701) Am J Gastroenterol. 2009 Mar;104(3):760-7. (PMID: 19174781) Gut. 2015 Oct;64(10):1539-45. (PMID: 25336114) J Gastroenterol. 2014 Apr;49(4):674-82. (PMID: 23666424) J Crohns Colitis. 2015 Jul;9(7):525-31. (PMID: 25895875) J Gastroenterol. 2012 Feb;47(2):136-43. (PMID: 21953314) |
| فهرسة مساهمة: | Keywords: Antibodies to infliximab; Crohn disease; Infliximab trough level; Loss of response; Mucosal healing |
| تواريخ الأحداث: | Date Created: 20180511 Latest Revision: 20220317 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC5934595 |
| DOI: | 10.5217/ir.2018.16.2.223 |
| PMID: | 29743835 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1598-9100 |
|---|---|
| DOI: | 10.5217/ir.2018.16.2.223 |